CALGARY, Alberta, July 30, 2019 /PRNewswire/ -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (CSE: XRX; OTCQB: XRTXF; ANU1: FWB), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that Dr. Allen Davidoff, CEO, will be presenting at VirtualInvestorConferences.com (www.VirtualInvestorConferences.com) on August 1st, a live, interactive online event where investors are invited to ask the Company questions in real-time – see details below.
DATE: Thursday, August 1st
TIME: 10:00 AM ET
XORTX invites individual and institutional investors, as well as advisors and analysts, and notes that if attendees are not able to join the live event on the day of the conference, an archived webcast will also be made available after the event. It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.
Dr. Allen Davidoff's presentation will highlight how XORTX is redefining how kidney disease is treated. The presentation outlines the critical issues facing millions of patients with progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease and the compelling studies and mounting evidence confirming XORTX's approach.
- XORTX has two lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease
- Clinical study evidence that XORTX's approach to uric acid lowering is key to treating and preventing chronic kidney disease
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has two lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. XORTX's XRx-008 (a proprietary reformulation of Oxypurinol) is a late stage drug development program to treat autosomal dominant polycystic kidney disease (ADPKD) and TMX-049, is a late phase 2b stage program to treat type 2 diabetic nephropathy (T2DN), under a co-development agreement with Japan's Teijin Pharma Limited, pursuant to a non-binding Letter of Intent. Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease. Additional information on XORTX Therapeutics is available at www.xortx.com.
About Virtual Investor ConferencesSM
Virtual Investor Conferences is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.
A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group's suite of investor relations services specifically designed for more efficient Investor Access. Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.
The CSE has neither approved nor disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
View original content to download multimedia:http://www.prnewswire.com/news-releases/xortx-announces-virtual-investor-conference-live-webcast-300892572.html